Remission of Metastatic Lesions Following Cryosurgery in Prostatic Cancer: Immunologic Considerations

Soanes, Ward A.; Ablin, Richard J.; Gonder, Maurice J.

doi:10.1016/s0022-5347(17)61690-2

Cited by 185 publications

(89 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data on antitumor responses in patients after local ablative treatment have only been reported incidentally (8,9). On the basis of our current knowledge on immune response induction in general, and the unique requirement for mature professional antigen-presenting cells in particular, the aforementioned results imply that immune activation following RFA is suboptimal.…”

Section: Discussionmentioning

confidence: 99%

“…For long it has been discussed whether ablated tumor debris is able to induce a systemic immune response; however, a systematic analysis has not been reported and therefore convincing evidence is lacking. Few studies report on an occasional patient with spontaneously regressing metastases and reduced numbers of developing secondary foci postablation (8,9). However, based on the results of vaccination studies with large amounts of irradiated autologous tumor cells or tumor lysates, it is not likely that a large amount of tumor debris by itself is sufficient to induce a potent antitumor response (10,11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Brok

Sutmuller²,

Voort³

et al. 2004

Cancer Research

373

284

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Brok

Sutmuller²,

Voort³

et al. 2004

Cancer Research

373

284

View full text Add to dashboard Cite

“…However, there have also been advances in the field of immunotherapy for the treatment of osteosarcoma that have received less attention (5,6). Following cryotreatment, the necrotic tumor lesion remains within the body, and the release of tumor antigens by dying cells has been hypothesized to activate a tumor-specific immune response via antigen presentation by antigen-presenting cells (APCs) such as dendritic cells (DCs) to T cells (7,8). A number of tumor studies combining immunomodulation methods such as the injection of Toll-like receptor agonists with cryotreatment have demonstrated a synergistic effect on tumor rejection, and this was attributed to the enhanced activation of APC function (9,10).…”

Section: Introductionmentioning

confidence: 99%

Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma

et al. 2013

View full text Add to dashboard Cite

Abstract.Immunotherapy with tumor lysate-loaded dendritic cells (DCs) is one of the most promising strategies to induce antitumor immune responses. However, the antitumor activity of cytotoxic T cells may be restrained by their expression of the inhibitory T-cell coreceptor cytotoxic T lymphocyte antigen-4 (CTLA-4). By relieving this restraint, CTLA-4-blocking antibodies promote tumor rejection, but the full scope of their most suitable applications has yet to be fully determined. In the present study, we offer proof of a preclinical concept in a C3H mouse osteosarcoma (LM8) model that CTLA-4 blockade cooperates with cryotreated tumor lysatepulsed DCs in a primary tumor to prevent the outgrowth of lung metastasis. To evaluate immune response activation, we established the following four groups of C3H mice (60 mice in total): i) control immunoglobulin G (IgG)-treated mice; ii) tumor lysate-pulsed DC-treated mice; iii) anti-CTLA-4 antibody-treated mice and iv) tumor lysate-pulsed DC-and anti-CTLA-4 antibody-treated mice. The mice that received the tumor lysate-pulsed DCs and anti-CTLA-4 antibody displayed reduced numbers of regulatory T lymphocytes and increased numbers of CD8 + T lymphocytes inside the metastatic tumor, inhibition of metastatic growth, a prolonged lifetime, reduced numbers of regulatory T lymphocytes in the spleen and high serum interferon-γ levels. Combining an anti-CTLA-4 antibody with tumor lysate-pulsed DCs enhanced the systemic immune response. To the best of our knowledge, these findings document for the first time an effect of the combination of tumor lysate-pulsed DCs and CTLA-4-blocking antibodies in osteosarcoma. We suggest that cryotreated tumor lysatepulsed DCs, although insufficient on their own, may mediate the rejection of metastatic lesions and prevent recurrence of the disease when combined with CTLA-4 blockade in osteosarcoma patients in the clinical setting. IntroductionOsteosarcoma is the most common primary malignant tumor of bone. Remarkable advances in the treatment of osteosarcoma have occurred, including the introduction of adjuvant chemotherapy and appropriate surgical excision (1-4). However, there have also been advances in the field of immunotherapy for the treatment of osteosarcoma that have received less attention (5,6). Following cryotreatment, the necrotic tumor lesion remains within the body, and the release of tumor antigens by dying cells has been hypothesized to activate a tumor-specific immune response via antigen presentation by antigen-presenting cells (APCs) such as dendritic cells (DCs) to T cells (7,8). A number of tumor studies combining immunomodulation methods such as the injection of Toll-like receptor agonists with cryotreatment have demonstrated a synergistic effect on tumor rejection, and this was attributed to the enhanced activation of APC function (9,10). We developed a method using cryotreated tumor tissue and DCs to enhance tumor-specific immunoreactions since DCs are the main APCs initiating cell-mediated immune responses in vivo (11,12).Mon...

show abstract

“…7 Sabel 8 describes the existing evidence of both stimu- seeding metastases of renal mass cryoablation latory and suppressive immune responses after cryoablation. In addition to the cryo-induced immunological response, there is evidence that an immune response is associated to the laparoscopy itself that may trigger inoculation of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Renal cancer seeding metastases following retroperitoneoscopic-assisted cryoablation: A case report

Kamp

Kortekaas²,

Lagerveld

2015

CUAJ

View full text Add to dashboard Cite

Nephron-sparing laparoscopy is the standard surgical treatment for clinical T1a renal tumours. However, the laparoscopic technique brings in its specific oncological safety concerns. Seeding metastases are reported: peritoneal metastases, port-tract metastases, and (sub-) cutaneous metastases. The method of laparoscopic assisted renal mass cryoablation is marked by the fact that traumatic tumour tissue handling is unavoidable. This case report reviews the rare occasion of seeding metastases in the retroperitoneal space following laparoscopic cryoablation of a small renal mass. The primary tumour showed no focal recurrence as reported by histological examination. The combination of two events as harming the integrity of cancer tissue and gas-circulation leading to the development of metastases in the retroperitoneal cavity is discussed. The combination of iatrogenic harming cancer tissue integrity and CO 2 -circulation leads to metastases in the retroperitoneal cavity. Therefore, we recommend performing image-guided renal mass biopsies before considering cryoablative surgery.

show abstract

Remission of Metastatic Lesions Following Cryosurgery in Prostatic Cancer: Immunologic Considerations

Cited by 185 publications

References 5 publications

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma

Renal cancer seeding metastases following retroperitoneoscopic-assisted cryoablation: A case report

Contact Info

Product

Resources

About